placeUnited Kingdom
Contact & Support
Medtronic / Clinical Solutions / Simplify Oesophageal Care

Difficult to diagnose

Challenging to Manage

Oesophageal disease patients can have similar symptoms — but their diseases may be different. This means tests aren't always conclusive and treatment isn't always effective:

  • Up to 50 percent of endoscopies for predominant oesophageal symptoms are negative.1-3
  • Nearly one-third of patients with suspected PPI-resistant nonerosive reflux disease may have an undiagnosed primary oesophageal motility disorder.4
  • One in three patients referred with ongoing symptoms while using PPIs doesn’t have GORD.5

Move beyond symptoms

With 2 simple tests

Our solutions help you objectively evaluate the root cause of oesophageal motility disorders and GORD:

  • Endoflip™ impedance planimetry system measures pressure and dimensions in real-time to evaluate suspected oesophageal motility disorders. Impedance planimetry of the upper gastrointestinal tract adds meaningfully to diagnostic evaluation and therapeutic decision-making.6
  • Bravo™ calibration-free reflux testing system measures acid levels in the oesophagus for up to 96 hours. Early diagnostic testing before long-term PPI initiation may help define which patients can avoid PPI use and potentially prevent excess PPI dependence.7

Clinical Evidence

Download and access the EndoflipTM Impedance Planimetry System Protocole & Interpretation white paper

Predictability for you. Options for your patients.

The right treatment for each patient depends on many factors. We provide resources to aide patients understand their conditions and empower themselves

Your partner in Oesophageal Care

Learn how our comprehensive portfolio can help you care for patients across the care continuum — from GORD to Barrett's oesophagus.

View Products

Speak with a Representative

For additional information about the EndoflipTM or BravoTM systems, complete a brief form to speak directly with a Medtronic sales representative.

  • 1. Laine, Goldmann et al. In the clinic: gastroesophageal reflux disease. Annals of Internal Medicine. 2008 Aug 5; ITC2: 1-16.

  • 2. Kahrilas PJ. Gastroesophageal reflux disease. N Engl J Med. 2008; 359: 1700-7.

  • 3. Ronkainen et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005; 129: 1825-1831.

  • 4. Kawamura O, Hosaka H, Shimoyama Y et al. Evaluation of proton pump inhibitor resistant nonerosive reflux disease by esophageal manometry and 24-hour esophageal impedance and pH monitoring. Digestion. 2015;91(1):19-25.

  • 5. Herregods, T. V. K., et al. Patients with refractory reflux symptoms often do not have GERD: Neurogastroenterology & Motility. 2015; 27(9): 1267-1273.

  • 6. Ahuja NK, Agnihotri A, Lynch KL, et al. Esophageal distensibility measurement: impact on clinical management and procedure length. Diseases Of The Esophagus: Official Journal Of The International Society For Diseases Of The Esophagus. 2017;30(8):1-8.

  • 7. Triadafilopoulos G, Zikos T, Regalia K, et al. Use of Esophageal pH Monitoring to Minimize Proton-Pump Inhibitor Utilization in Patients with Gastroesophageal Reflux Symptoms. Digestive Diseases And Sciences. 2018;63(10):2673-2680. doi:10.1007/s10620-018-5183-4.

Corporate Resources
Medical Surgical Portfolio
Additional Resources
Contact Us
Medtronic Limited

Building 9, Croxley Park

Hatters Lane

Watford, WD18 8WW

United Kingdom

©2024 Medtronic